Vanguard Investments Australia
INBX icon

Vanguard Investments Australia’s Inhibrx INBX Stock Holding History

Vanguard Investments Australia’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198K Hold
2,090
– – ﹤0.01% 2119
2026
Q1 		$141K Buy
+2,090
New +$155K ﹤0.01% 2182

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Investments Australia's INBX Position: Q2 2026 in Review

Vanguard Investments Australia held its Inhibrx (INBX) position steady in Q2 2026 at 2,090 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #2119.

Vanguard Investments Australia first reported a position in INBX in Q1 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Vanguard Investments Australia held 2,090 shares of Inhibrx worth $198K as of Q2 2026.
  • Vanguard Investments Australia left its Inhibrx share count unchanged in Q2 2026.
  • Inhibrx made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2119 holding.
  • Vanguard Investments Australia first reported a position in Inhibrx in Q1 2026 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.